GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » PE Ratio (TTM)

Orgenesis (Orgenesis) PE Ratio (TTM) : At Loss (As of Apr. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-25), Orgenesis's share price is $0.507. Orgenesis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.61. Therefore, Orgenesis's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Orgenesis's PE Ratio (TTM) or its related term are showing as below:

ORGS' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 2.2   Max: 8.98
Current: At Loss


During the past 13 years, the highest PE Ratio (TTM) of Orgenesis was 8.98. The lowest was 0.00. And the median was 2.20.


ORGS's PE Ratio (TTM) is ranked worse than
100% of 250 companies
in the Biotechnology industry
Industry Median: 27.125 vs ORGS: At Loss

Orgenesis's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-1.16. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.61.

As of today (2024-04-25), Orgenesis's share price is $0.507. Orgenesis's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.40. Therefore, Orgenesis's PE Ratio without NRI for today is At Loss.

Orgenesis's EPS without NRI for the three months ended in Dec. 2023 was $-0.96. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.40.

During the past 3 years, the average EPS without NRI Growth Rate was 27.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 2.50% per year.

During the past 13 years, Orgenesis's highest 3-Year average EPS without NRI Growth Rate was 27.00% per year. The lowest was -610.90% per year. And the median was 1.25% per year.

Orgenesis's EPS (Basic) for the three months ended in Dec. 2023 was $-1.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.61.


Orgenesis PE Ratio (TTM) Historical Data

The historical data trend for Orgenesis's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis PE Ratio (TTM) Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss 15.52 At Loss At Loss At Loss

Orgenesis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Orgenesis's PE Ratio (TTM)

For the Biotechnology subindustry, Orgenesis's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Orgenesis's PE Ratio (TTM) falls into.



Orgenesis PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Orgenesis's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.507/-2.610
=At Loss

Orgenesis's Share Price of today is $0.507.
Orgenesis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.61.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Orgenesis  (NAS:ORGS) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Orgenesis PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Orgenesis's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (Orgenesis) Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Executives
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452